Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial

Dasgupta I, Meadowcroft AM, Bhatt PR, Acharya A, Aarup M, Correa-Rotter R, Gupta S, Kher VK, Neto OMV, Rastogi A, Ots-Rosenberg M, Rayner B, Wong[...]

Insulin-producing cells derived from expandable stem cell-derived endoderm are effective for the treatment of type 2 diabetes

Yoshihara E. Insulin-producing cells derived from expandable stem cell-derived endoderm are effective for the treatment of type 2 diabetes. Ann Transl Med. 2024 Dec 24;12(6):121.[...]

Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes[...]